Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Radiation-induced alternative transcripts as detected in total and polysome-bound mRNA.

Wahba A, Ryan MC, Shankavaram UT, Camphausen K, Tofilon PJ.

Oncotarget. 2017 Oct 9;9(1):691-705. doi: 10.18632/oncotarget.21672. eCollection 2018 Jan 2.

2.

Correction to expert consensus on re-irradiation for recurrent glioma.

Krauze AV, Attia A, Braunstein S, Chan M, Combs SE, Fietkau R, Fiveash J, Flickinger J, Grosu A, Howard S, Nieder C, Niyazi M, Rowe L, Smart DD, Tsien C, Camphausen K.

Radiat Oncol. 2018 Jan 18;13(1):8. doi: 10.1186/s13014-018-0955-8.

3.

Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.

Hao S, Song H, Zhang W, Seldomridge A, Jung J, Giles AJ, Hutchinson MK, Cao X, Colwell N, Lita A, Larion M, Maric D, Abu-Asab M, Quezado M, Kramp T, Camphausen K, Zhuang Z, Gilbert MR, Park DM.

Neuro Oncol. 2017 Dec 23. doi: 10.1093/neuonc/nox241. [Epub ahead of print]

PMID:
29294092
4.

LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation.

Ho WS, Sizdahkhani S, Hao S, Song H, Seldomridge A, Tandle A, Maric D, Kramp T, Lu R, Heiss JD, Camphausen K, Gilbert MR, Zhuang Z, Park DM.

Cancer Lett. 2018 Feb 28;415:217-226. doi: 10.1016/j.canlet.2017.11.035. Epub 2017 Dec 2.

PMID:
29199006
5.

Expert consensus on re-irradiation for recurrent glioma.

Krauze AV, Attia A, Braunstein S, Chan M, Combs SE, Fietkau R, Fiveash J, Flickinger J, Grosu A, Howard S, Nieder C, Niyazi M, Rowe L, Smart DD, Tsien C, Camphausen K.

Radiat Oncol. 2017 Dec 1;12(1):194. doi: 10.1186/s13014-017-0928-3. Erratum in: Radiat Oncol. 2018 Jan 18;13(1):8.

6.

Biodosimetry: A Future Tool for Medical Management of Radiological Emergencies.

Sproull MT, Camphausen KA, Koblentz GD.

Health Secur. 2017 Nov/Dec;15(6):599-610. doi: 10.1089/hs.2017.0050. Epub 2017 Dec 1.

PMID:
29193982
7.

Re-irradiation for recurrent glioma- the NCI experience in tumor control, OAR toxicity and proposal of a novel prognostic scoring system.

Krauze AV, Peters C, Cheng J, Ning H, Mackey M, Rowe L, Cooley-Zgela T, Smart DD, Camphausen K.

Radiat Oncol. 2017 Nov 29;12(1):191. doi: 10.1186/s13014-017-0930-9.

8.

Quantitative imaging of pO2 in orthotopic murine gliomas: hypoxia correlates with resistance to radiation.

Yasui H, Kawai T, Matsumoto S, Saito K, Devasahayam N, Mitchell JB, Camphausen K, Inanami O, Krishna MC.

Free Radic Res. 2017 Oct;51(9-10):861-871. doi: 10.1080/10715762.2017.1388506.

PMID:
29076398
9.

Brain tumor segmentation using holistically nested neural networks in MRI images.

Zhuge Y, Krauze AV, Ning H, Cheng JY, Arora BC, Camphausen K, Miller RW.

Med Phys. 2017 Oct;44(10):5234-5243. doi: 10.1002/mp.12481. Epub 2017 Aug 20.

PMID:
28736864
10.

Optimizing the Benefit of CNS Radiation Therapy in the Pediatric Population-PART 2: Novel Methods of Radiation Delivery.

Rowe LS, Krauze AV, Ning H, Camphausen KA, Kaushal A.

Oncology (Williston Park). 2017 Mar 15;31(3):224-6, 228. Review.

11.

Optimizing the Benefit of CNS Radiation Therapy in the Pediatric Population-PART 1: Understanding and Managing Acute and Late Toxicities.

Rowe LS, Krauze AV, Ning H, Camphausen KA, Kaushal A.

Oncology (Williston Park). 2017 Mar 15;31(3):182-8. Review.

12.

Computational analysis of the mesenchymal signature landscape in gliomas.

Celiku O, Tandle A, Chung JY, Hewitt SM, Camphausen K, Shankavaram U.

BMC Med Genomics. 2017 Mar 9;10(1):13. doi: 10.1186/s12920-017-0252-7.

14.

Multivariate Analysis of Radiation Responsive Proteins to Predict Radiation Exposure in Total-Body Irradiation and Partial-Body Irradiation Models.

Sproull M, Kramp T, Tandle A, Shankavaram U, Camphausen K.

Radiat Res. 2017 Feb;187(2):251-258. doi: 10.1667/RR14558.1. Epub 2017 Jan 24.

15.

Mitotic Protein Kinase 1: Role in Spindle Assembly Checkpoint Revisited.

Tandle A, Camphausen K.

J Cancer Clin Trials. 2016 May;1(2). pii: 111. Epub 2016 May 2. No abstract available.

16.

FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells.

Maachani UB, Shankavaram U, Kramp T, Tofilon PJ, Camphausen K, Tandle AT.

Oncotarget. 2016 Nov 22;7(47):77365-77377. doi: 10.18632/oncotarget.12670.

17.

State-of-the-Art Advances in Radiation Biodosimetry for Mass Casualty Events Involving Radiation Exposure.

Sproull M, Camphausen K.

Radiat Res. 2016 Nov;186(5):423-435. Epub 2016 Oct 6. Review.

18.

A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.

Zhen DB, Griffith KA, Ruch JM, Camphausen K, Savage JE, Kim EJ, Sahai V, Simeone DM, Zalupski MM.

Invest New Drugs. 2016 Dec;34(6):733-739. Epub 2016 Jul 21.

PMID:
27439894
19.

Polysome Profiling Links Translational Control to the Radioresponse of Glioblastoma Stem-like Cells.

Wahba A, Rath BH, Bisht K, Camphausen K, Tofilon PJ.

Cancer Res. 2016 May 15;76(10):3078-87. doi: 10.1158/0008-5472.CAN-15-3050. Epub 2016 Mar 22.

20.

Coculture with astrocytes reduces the radiosensitivity of glioblastoma stem-like cells and identifies additional targets for radiosensitization.

Rath BH, Wahba A, Camphausen K, Tofilon PJ.

Cancer Med. 2015 Nov;4(11):1705-16. doi: 10.1002/cam4.510. Epub 2015 Oct 30.

21.

Molecular profiling of MPS1 gene silencing in U251 glioma cell line.

Shankavaram U, Maachani UB, Zhao S, Camphausen K, Tandle A.

Genom Data. 2015 Dec 1;6:36-39.

22.

Analysis of radiation therapy in a model of triple-negative breast cancer brain metastasis.

Smart D, Garcia-Glaessner A, Palmieri D, Wong-Goodrich SJ, Kramp T, Gril B, Shukla S, Lyle T, Hua E, Cameron HA, Camphausen K, Steeg PS.

Clin Exp Metastasis. 2015 Oct;32(7):717-27. doi: 10.1007/s10585-015-9739-9. Epub 2015 Aug 30.

PMID:
26319493
23.

A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.

Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S, Shih J, Tofilon PJ, Fine HA, Camphausen K.

Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):986-992. doi: 10.1016/j.ijrobp.2015.04.038. Epub 2015 Apr 30.

24.

Serum Amyloid A as a Biomarker for Radiation Exposure.

Sproull M, Kramp T, Tandle A, Shankavaram U, Camphausen K.

Radiat Res. 2015 Jul;184(1):14-23. Epub 2015 Jun 26.

25.

Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients.

Jones GC, Kehrer JD, Kahn J, Koneru BN, Narayan R, Thomas TO, Camphausen K, Mehta MP, Kaushal A.

Clin Lung Cancer. 2015 Nov;16(6):413-30. doi: 10.1016/j.cllc.2015.04.001. Epub 2015 Apr 23. Review.

26.

Modulation of miR-21 signaling by MPS1 in human glioblastoma.

Maachani UB, Tandle A, Shankavaram U, Kramp T, Camphausen K.

Oncotarget. 2016 Aug 16;7(33):52912-52927. doi: 10.18632/oncotarget.4143.

27.

Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma.

Gordon IK, Lu J, Graves CA, Huntoon K, Frerich JM, Hanson RH, Wang X, Hong CS, Ho W, Feldman MJ, Ikejiri B, Bisht K, Chen XS, Tandle A, Yang C, Arscott WT, Ye D, Heiss JD, Lonser RR, Camphausen K, Zhuang Z.

Mol Cancer Ther. 2015 Jul;14(7):1540-1547. doi: 10.1158/1535-7163.MCT-14-0614. Epub 2015 May 4.

28.

Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.

Maachani UB, Kramp T, Hanson R, Zhao S, Celiku O, Shankavaram U, Colombo R, Caplen NJ, Camphausen K, Tandle A.

Mol Cancer Res. 2015 May;13(5):852-62. doi: 10.1158/1541-7786.MCR-14-0462-T. Epub 2015 Feb 26.

29.

Current clinical trials testing combinations of immunotherapy and radiation.

Crittenden M, Kohrt H, Levy R, Jones J, Camphausen K, Dicker A, Demaria S, Formenti S.

Semin Radiat Oncol. 2015 Jan;25(1):54-64. doi: 10.1016/j.semradonc.2014.07.003. Review.

30.

Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Kahn J, Gillespie A, Tsokos M, Ondos J, Dombi E, Camphausen K, Widemann BC, Kaushal A.

Front Oncol. 2014 Nov 17;4:324. doi: 10.3389/fonc.2014.00324. eCollection 2014.

31.

A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma.

Wuthrick EJ, Curran WJ Jr, Camphausen K, Lin A, Glass J, Evans J, Andrews DW, Axelrod R, Shi W, Werner-Wasik M, Haacke EM, Hillman GG, Dicker AP.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):369-75. doi: 10.1016/j.ijrobp.2014.05.034. Epub 2014 Aug 4.

PMID:
25104067
32.

A prospective study of mediastinal gray-zone lymphoma.

Wilson WH, Pittaluga S, Nicolae A, Camphausen K, Shovlin M, Steinberg SM, Roschewski M, Staudt LM, Jaffe ES, Dunleavy K.

Blood. 2014 Sep 4;124(10):1563-9. doi: 10.1182/blood-2014-03-564906. Epub 2014 Jul 14.

33.

External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma.

Vogel J, Atanacio AS, Prodanov T, Turkbey BI, Adams K, Martucci V, Camphausen K, Fojo AT, Pacak K, Kaushal A.

Front Oncol. 2014 Jun 27;4:166. doi: 10.3389/fonc.2014.00166. eCollection 2014.

34.

Visualizing molecular profiles of glioblastoma with GBM-BioDP.

Celiku O, Johnson S, Zhao S, Camphausen K, Shankavaram U.

PLoS One. 2014 Jul 10;9(7):e101239. doi: 10.1371/journal.pone.0101239. eCollection 2014.

35.

microRNA alterations driving acute and late stages of radiation-induced fibrosis in a murine skin model.

Simone BA, Ly D, Savage JE, Hewitt SM, Dan TD, Ylaya K, Shankavaram U, Lim M, Jin L, Camphausen K, Mitchell JB, Simone NL.

Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):44-52. doi: 10.1016/j.ijrobp.2014.05.003. Epub 2014 Jun 28.

PMID:
24986745
36.

Magnetic resonance imaging of the tumor microenvironment in radiotherapy: perfusion, hypoxia, and metabolism.

Matsuo M, Matsumoto S, Mitchell JB, Krishna MC, Camphausen K.

Semin Radiat Oncol. 2014 Jul;24(3):210-7. doi: 10.1016/j.semradonc.2014.02.002. Review.

37.

The metastatic potential of triple-negative breast cancer is decreased via caloric restriction-mediated reduction of the miR-17~92 cluster.

Jin L, Lim M, Zhao S, Sano Y, Simone BA, Savage JE, Wickstrom E, Camphausen K, Pestell RG, Simone NL.

Breast Cancer Res Treat. 2014 Jul;146(1):41-50. doi: 10.1007/s10549-014-2978-7. Epub 2014 May 27.

38.

Bringing the heavy: carbon ion therapy in the radiobiological and clinical context.

Schlaff CD, Krauze A, Belard A, O'Connell JJ, Camphausen KA.

Radiat Oncol. 2014 Mar 28;9(1):88. doi: 10.1186/1748-717X-9-88. Review.

39.

Ionizing radiation and glioblastoma exosomes: implications in tumor biology and cell migration.

Arscott WT, Tandle AT, Zhao S, Shabason JE, Gordon IK, Schlaff CD, Zhang G, Tofilon PJ, Camphausen KA.

Transl Oncol. 2013 Dec 1;6(6):638-48. eCollection 2013 Dec 1.

40.

The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.

Kahn J, Hayman TJ, Jamal M, Rath BH, Kramp T, Camphausen K, Tofilon PJ.

Neuro Oncol. 2014 Jan;16(1):29-37. doi: 10.1093/neuonc/not139. Epub 2013 Dec 4.

41.

CD44 is prognostic for overall survival in the NCI randomized trial on breast conservation with 25 year follow-up.

Dan T, Hewitt SM, Ohri N, Ly D, Soule BP, Smith SL, Matsuda K, Council C, Shankavaram U, Lippman ME, Mitchell JB, Camphausen K, Simone NL.

Breast Cancer Res Treat. 2014 Jan;143(1):11-8. doi: 10.1007/s10549-013-2758-9. Epub 2013 Nov 26.

PMID:
24276281
42.

Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer.

Prager AJ, Peng CR, Lita E, McNally D, Kaushal A, Sproull M, Compton K, Dahut WL, Figg WD, Citrin D, Camphausen KA.

Biomark Med. 2013 Dec;7(6):831-41. doi: 10.2217/bmm.13.112.

PMID:
24266816
43.

Biomarkers to guide therapy or surveillance for prostate cancer.

Citrin D, Hudak K, Camphausen KA.

Biomark Med. 2013 Dec;7(6):827-9. doi: 10.2217/bmm.13.123. No abstract available.

44.

Biomarkers for prostate cancer: who will benefit from local treatment, who harbors occult systemic disease and who needs treatment at all?

Citrin D, Camphausen KA.

Biomark Med. 2013 Dec;7(6):823-5. doi: 10.2217/bmm.13.127. No abstract available.

45.

Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM).

Krauze AV, Won M, Graves C, Corn BW, Muanza TM, Howard SP, Mahadevan A, Schultz CJ, Haas ML, Mehta MP, Camphausen KA.

Biomark Res. 2013 Oct 31;1(1):29. doi: 10.1186/2050-7771-1-29.

46.

The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells.

Hayman TJ, Wahba A, Rath BH, Bae H, Kramp T, Shankavaram UT, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2014 Jan 1;20(1):110-9. doi: 10.1158/1078-0432.CCR-13-2136. Epub 2013 Nov 6.

47.

Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.

Ho J, Ondos J, Ning H, Smith S, Kreisl T, Iwamoto F, Sul J, Kim L, McNeil K, Krauze A, Shankavaram U, Fine HA, Camphausen K.

PLoS One. 2013 Aug 5;8(8):e70745. doi: 10.1371/journal.pone.0070745. Print 2013.

48.

Role of radiotherapy in adrenocortical carcinoma.

Ho J, Turkbey B, Edgerly M, Alimchandani M, Quezado M, Camphausen K, Fojo T, Kaushal A.

Cancer J. 2013 Jul-Aug;19(4):288-94. doi: 10.1097/PPO.0b013e31829e3221.

PMID:
23867507
49.

Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.

Tandle AT, Kramp T, Kil WJ, Halthore A, Gehlhaus K, Shankavaram U, Tofilon PJ, Caplen NJ, Camphausen K.

Eur J Cancer. 2013 Sep;49(14):3020-8. doi: 10.1016/j.ejca.2013.05.013. Epub 2013 Jun 18.

50.

Competitive but Not Allosteric mTOR Kinase Inhibition Enhances Tumor Cell Radiosensitivity.

Hayman TJ, Kramp T, Kahn J, Jamal M, Camphausen K, Tofilon PJ.

Transl Oncol. 2013 Jun 1;6(3):355-62. Print 2013 Jun.

Supplemental Content

Loading ...
Support Center